Skip to content

Correlation between serum insulin-like growth factor 1 and diabetic peripheral neuropathy in T2DM patients

Correlation between serum insulin-like growth factor 1 and diabetic peripheral neuropathy in T2DM patients

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200058111
Enrollment
Unknown
Registered
2022-03-30
Start date
2022-04-01
Completion date
Unknown
Last updated
2023-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic peripheral neuropathy

Interventions

diabetic peripheral neuropathy:nothing
diabetes without peripheral neuropathy:nothing

Sponsors

Shenzhen Hospital of Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.The selected patients need to sign informed consent. 2.The patients diagnose diabetes according to the 1999 WHO diagnostic criteria for type 2 diabetes mellitus. 3.All patients must be =18 years old.

Exclusion criteria

Exclusion criteria: 1.The other causes for neuropathy including spondylopathy like radiculopathy, spinal stenosis, spondylosis, and cerebral infarction, Guillain-Barre syndrome, severe vascular disease, infection, immune abnormalities, drug-induced nerve injury , nutritional deficiencies, congenital diseases, trauma, etc. 2.The other causes for abnormal glucose and lipid metabolism including hyperthyroidism, hypothyroidism, Cushing's syndrome, hypothalamic and pituitary lesions, long-term use of glucocorticoids ,etc. 3.Type 1 diabetes, gestational diabetes. 4.The acute complications of diabetes including diabetic ketoacidosis, hyperglycemic hyperosmolar nonketotic coma. 5.The patients with severe liver disease, heart disease, long-term use of antibiotic, acute or chronic infection . 6.The pregnant women and those who plans to become pregnant. 7.The patients with acute or chronic infectious diseases and cancer. 8.Subjects who can't sign informed consent.

Design outcomes

Primary

MeasureTime frame
Insulin-like growth factor 1;Nerve conduction velocity;Sympathetic skin response;F wave;Quantitative sensory testing;

Countries

China

Contacts

Public ContactXu Lingling
lucylingl@126.com13538838066

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026